IDYA (IDEAYA Biosciences) 10-Year Sortino Ratio: N/A (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IDYA IDEAYA Biosciences Inc IDYA
53 GF Score
Price $38.86
GF Value $186.18
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IDEAYA Biosciences 10-Year Sortino Ratio?

The 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. As of today (2026-09-22), IDEAYA Biosciences's 10-Year Sortino Ratio is Not available.


IDEAYA Biosciences  (NAS:IDYA) 10-Year Sortino Ratio Explanation

The 10-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past ten year. It is calculated as the annualized result of the average ten-year monthly excess returns divided by the standard deviation of negative returns in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


IDEAYA Biosciences 10-Year Sortino Ratio Related Terms


IDYA vs LEGN, DNLI, TNGX: 10-Year Sortino Ratio Comparison

For the Biotechnology subindustry, IDEAYA Biosciences's 10-Year Sortino Ratio, along with its competitors' market caps and 10-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEAYA Biosciences 10-Year Sortino Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's 10-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's 10-Year Sortino Ratio falls into.


IDYA
53GF Score
IDEAYA Biosciences Inc IDYA
10-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEAYA Biosciences 10-Year Sortino Ratio Calculation

The 10-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last ten year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 10-Year Sortino Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past ten year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Is IDEAYA Biosciences (IDYA) Overvalued in 2026?

Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued. The current stock price of $38.86 is trading 79.1% below its estimated GF Value™ of $186.18. GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.

Key valuation signals for IDYA:

  • 10-Year Sortino Ratio: N/A
  • GF Value™: $186.18 vs. price of $38.86 (79.1% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IDEAYA Biosciences Business Description

Other Exchanges 30J:Germany
Address 5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
53GF Score

Get the complete analysis for IDYA

10-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.86
Price
$186.18
GF Value